50.89 0.00 (0.00%)
After hours: 5:11PM EST
|Bid||50.48 x 900|
|Ask||57.00 x 800|
|Day's range||50.81 - 52.86|
|52-week range||16.69 - 58.48|
|Beta (3Y monthly)||0.88|
|PE ratio (TTM)||N/A|
|Earnings date||30 Oct 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||69.46|
The Medicines Company (MDCO) misses earnings estimates in Q3. The company is progressing well with its sole pipeline candidate, inclisiran.
Medicines Co. (MDCO) delivered earnings and revenue surprises of -9.52% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
The Medicines Company's (MDCO) PCSK9 inhibitor, inclisiran, meets primary endpoint of LDL-C reduction in the remaining two phase III studies in the ORION program. Shares up.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of The Medicines Company...
Alnylam (ALNY) starts phase III APOLLO-B study on its lead drug Onpattro for treating transthyretin amyloidosis with cardiomyopathy. Shares rise.
On a day when trade worries and weak economic data hurt stocks, Medicines Company rose on a successful drug trial and Boston Beer fell following a downgrade.
Medicines Co. (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.
Vabomere and Minocin are expected to drive Melinta's (MLNT) second-quarter revenues. Operating expenses are likely to be lower. The company may provide update on progress of Baxdela label expansion.
The Medicines Company (MDCO) posts narrower-than-expected loss in Q2. The company did not generate any revenues in the period while its focus is steady on its sole pipeline candidate, inclisiran.
Medicines Co. (MDCO) delivered earnings and revenue surprises of 4.55% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?